Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was ranked No. 3 on The Medicine Maker Power List 2026 in the Small Molecules category, recognizing his leadership in oncology drug development. Under his guidance, Ascentage Pharma has advanced innovative cancer therapies like olverembatinib and lisaftoclax, both approved in China and currently in global Phase III trials. This accolade highlights the company's impact on global pharmaceutical innovation and its commitment to addressing unmet medical needs in cancer treatment. The company continues to expand its global development efforts and partnerships to bring new therapies to patients worldwide.
Toescoin, a memecoin on the Solana blockchain, announced talks with a major Japanese venture capital firm interested in investing up to $250,000 over time. This engagement aims to provide both funding and strategic support as Toescoin expands its pre...
XRP is trading in a narrow range around $1.10 as Ripple advances key upgrades to its XRP Ledger (XRPL), including new server software and automated market maker enhancements. The ecosystem also benefits from expanding stablecoin use with RLUSD and re...
Solana (SOL) is consolidating around $75, supported by the validator-approved Alpenglow upgrade aimed at faster transaction finality and strong on-chain activity with 18 million weekly active addresses. Despite a recent correction, SOL shows medium-t...
Spotify's stock price has dropped 30% from its all-time high, but this decline does not reflect the company's solid business fundamentals. The company shows strong growth in monthly active users and premium subscribers, supported by geographic divers...
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was named No. 3 in the Small Molecules category on The Medicine Maker Power List 2026, recognizing his leadership in innovative cancer drug development. Under his guidance, Ascentage Pharma has ad...
